Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2020.0001
• Publication Date: 2020-01-07T20:45:18Z
• Authors: Patrick Brown; Hiroto Inaba; Colleen Annesley; Jill Beck; Susan Colace; Mari Dallas; Kenneth DeSantes; Kara Kelly; Carrie Kitko; Norman Lacayo; Nicole Larrier; Luke Maese; Kris Mahadeo; Ronica Nanda; Valentina Nardi; Vilmarie Rodriguez; Jenna Rossoff; Laura Schuettpelz; Lewis Silverman; Jessica Sun; Weili Sun; David Teachey; Victor Wong; Gregory Yanik; Alyse Johnson-Chilla; Ndiya Ogba
• Keywords: Evidence-Based Medicine; Organizations, Nonprofit; Age Factors; Hematopoietic Stem Cell Transplantation; Infant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Medical Oncology; United States; 3. Good health; Survival Rate; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Drug Resistance, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Transplantation, Homologous; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Child; SEER Program

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.